Cardiac energy metabolism is disturbed in Fabry disease and improves with enzyme replacement therapy using recombinant human galactosidase A

No abstract is available for this paper.

• Publication year

  2011

• Venue

  European Journal of Heart Failure

• Publication date

  2011-03-01

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1093/eurjhf/hfq211PMID 21149315
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Screening for Fabry disease using genetic testing

  2010cited by this paper
• Association between cardiac energy metabolism and gain of left ventricular mass in Fabry disease.

  2010cited by this paper
• Fabry disease mimicking hypertrophic cardiomyopathy: genetic screening needed for establishing the diagnosis in women

  2010cited by this paper
• Long-Term Effects of Enzyme Replacement Therapy on Fabry Cardiomyopathy: Evidence for a Better Outcome With Early Treatment

  2009cited by this paper
• Reduced Myocardial Creatine Kinase Flux in Human Myocardial Infarction: An In Vivo Phosphorus Magnetic Resonance Spectroscopy Study

  2009cited by this paper
• Impaired left ventricular energy metabolism in patients with hypertrophic cardiomyopathy is related to the extension of fibrosis at delayed gadolinium-enhanced magnetic resonance imaging

  2008cited by this paper
• Effects of exercise training on myocardial energy metabolism and ventricular function assessed by quantitative phosphorus-31 magnetic resonance spectroscopy and magnetic resonance imaging in dilated cardiomyopathy.

  2008cited by this paper
• Recommendations and guidelines for the diagnosis and treatment of Fabry nephropathy in adults

  2008cited by this paper
• The failing heart--an engine out of fuel.

  2007cited by this paper
• MRI characterization of myocardial tissue in patients with Fabry's disease.

  2007cited by this paper
• Agalsidase-Beta Therapy for Advanced Fabry Disease

  2007cited by this paper
• Effects of enzyme replacement therapy on the cardiomyopathy of Anderson–Fabry disease: a randomised, double-blind, placebo-controlled clinical trial of agalsidase alfa

  2007cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006cited by this paper
• The histological basis of late gadolinium enhancement cardiovascular magnetic resonance in a patient with Anderson-Fabry disease.

  2006cited by this paper
• Cardiac and Vascular Hypertrophy in Fabry Disease: Evidence for a New Mechanism Independent of Blood Pressure and Glycosphingolipid Deposition

  2006cited by this paper
• Impact of enzyme replacement therapy on cardiac morphology and function and late enhancement in Fabry's cardiomyopathy.

  2006influential reference
• Age and gender dependence of human cardiac phosphorus metabolites determined by SLOOP 31P MR spectroscopy

  2006cited by this paper
• Fabry disease: clinical spectrum and evidence-based enzyme replacement therapy.

  2006cited by this paper
• Fabry disease: reduced activities of respiratory chain enzymes with decreased levels of energy-rich phosphates in fibroblasts.

  2004cited by this paper
• Regulation of the mitochondrial ATP-synthase in health and disease.

  2003cited by this paper
• Fabry disease: diagnosis and treatment.

  2003cited by this paper
• Gadolinium enhanced cardiovascular magnetic resonance in Anderson-Fabry disease. Evidence for a disease specific abnormality of the myocardial interstitium.

  2003influential reference
• Fabry Disease, an Under-Recognized Multisystemic Disorder: Expert Recommendations for Diagnosis, Management, and Enzyme Replacement Therapy

  2003cited by this paper
• Absolute concentrations of high-energy phosphate metabolites in normal, hypertrophied, and failing human myocardium measured noninvasively with (31)P-SLOOP magnetic resonance spectroscopy.

  2002cited by this paper
• Natural history of Fabry disease in affected males and obligate carrier females

  2001cited by this paper
• Aortic valve replacement in patients with aortic valve stenosis improves myocardial metabolism and diastolic function.

  2001cited by this paper
• Age- and gender-specific differences in left and right ventricular cardiac function and mass determined by cine magnetic resonance imaging

  2000cited by this paper
• Concentrations of human cardiac phosphorus metabolites determined by SLOOP 31P NMR spectroscopy

  1999cited by this paper
• Altered Mitochondrial Function in Canine Ceroid-Lipofuscinosis

  1998cited by this paper
• Improved method for accurate and efficient quantification of MRS data with use of prior knowledge

  1997cited by this paper
• Myocardial phosphocreatine-to-ATP ratio is a predictor of mortality in patients with dilated cardiomyopathy.

  1997cited by this paper
• Detection of myocardial ischemia by [31]P magnetic resonance spectroscopy during handgrip exercise

  1995cited by this paper
• Detection of myocardial ischemia by 31P magnetic resonance spectroscopy during handgrip exercise.

  1994cited by this paper
• The true T1 values of myocardial high‐energy phosphates?

  1993cited by this paper
• Regulation of the mitochondrial ATP synthase in intact rat cardiomyocytes.

  1990cited by this paper
• Energetic correlates of cardiac failure: changes in the creatine kinase system in the failing myocardium.

  1990cited by this paper
• Lysosphingolipids and mitochondrial function. II. Deleterious effects of sphingosylphosphorylcholine.

  1988cited by this paper

• Czech nationwide screening for Fabry disease in patients on maintenance dialysis: a call for evaluation of population-enriched GLA gene variants of uncertain significance

  2025cites this paper
• Sex Differences in Circulating Inflammatory, Immune, and Tissue Growth Markers Associated with Fabry Disease-Related Cardiomyopathy

  2025cites this paper
• GLA deficiency causes cardiac hypertrophy via enhanced autophagy

  2025cites this paper
• Anxiety-like behavior and altered hippocampal activity in a transgenic mouse model of Fabry disease.

  2025cites this paper
• Inflammation in Fabry disease: stages, molecular pathways, and therapeutic implications

  2024cites this paper
• Glycosphingolipids in Cardiovascular Disease: Insights from Molecular Mechanisms and Heart Failure Models

  2024cites this paper
• Mechano-energetic uncoupling in hypertrophic cardiomyopathy: Pathophysiological mechanisms and therapeutic opportunities

  2023cites this paper
• Circulated TGF-β1 and VEGF-A as Biomarkers for Fabry Disease-Associated Cardiomyopathy

  2023cites this paper
• Biochemical Mechanisms beyond Glycosphingolipid Accumulation in Fabry Disease: Might They Provide Additional Therapeutic Treatments?

  2023cites this paper
• Nationwide screening of Fabry disease in patients with hypertrophic cardiomyopathy in Czech Republic

  2022cites this paper
• Cardiac ^31P MR spectroscopy: development of the past five decades and future vision—will it be of diagnostic use in clinics?

  2022cites this paper
• The Heart in Fabry Disease: Mechanisms Beyond Storage and Forthcoming Therapies

  2022cites this paper
• Defective lysosomal storage in Fabry disease modifies mitochondrial structure, metabolism and turnover in renal epithelial cells

  2021cites this paper
• Pathogenesis and Molecular Mechanisms of Anderson–Fabry Disease and Possible New Molecular Addressed Therapeutic Strategies

  2021cites this paper
• Lysosomal Storage Disorders: Fabry Disease

  2021cites this paper
• The Cardiovascular Phenotype in Fabry Disease: New Findings in the Research Field

  2021cites this paper
• Left ventricular radial strain impairment precedes hypertrophy in Anderson–Fabry disease

  2020cites this paper
• Treatment of Anderson-Fabry disease.

  2020cites this paper
• Altered Sphingolipids Metabolism Damaged Mitochondrial Functions: Lessons Learned From Gaucher and Fabry Diseases

  2020cites this paper
• An expert consensus document on the management of cardiovascular manifestations of Fabry disease

  2020cites this paper
• The effect of enzyme replacement therapy on clinical outcomes in male patients with Fabry disease: A systematic literature review by a European panel of experts

  2019cites this paper
• Inhibition of Mitochondrial Complex I Impairs Release of α-Galactosidase by Jurkat Cells

  2019cites this paper
• Elevated Inflammatory Plasma Biomarkers in Patients With Fabry Disease: A Critical Link to Heart Failure With Preserved Ejection Fraction

  2018influential citation
• Effects of Enzyme Replacement Therapy and Antidrug Antibodies in Patients with Fabry Disease.

  2018cites this paper
• Early markers of heart and kidney damage in Fabry disease

  2018cites this paper
• Uric Acid as a Marker of Mortality and Morbidity in Fabry Disease

  2016cites this paper
• Pharmacotherapy of inborn errors of metabolism illustrating challenges in orphan diseases.

  2016cites this paper
• Myocardial fibrosis pathology in Anderson–Fabry disease: Evaluation of autopsy cases in the long- and short-term enzyme replacement therapy, and non-therapy case

  2016cites this paper
• MRS studies of creatine kinase metabolism in human heart

  2016cites this paper
• Relationship between left ventricular diastolic function and myocardial sympathetic denervation measured by 123I-meta-iodobenzylguanidine imaging in Anderson-Fabry disease

  2016influential citation
• Two repetition time saturation transfer (TwiST) with spill-over correction to measure creatine kinase reaction rates in human hearts

  2015cites this paper
• Accurate and Efficient Localized Spectroscopy from Anatomically Matched Regions: SLOOP and Its Enhancements

  2015cites this paper
• Cardiac Energetic Impairment in Heart Disease and the Potential Role of Metabolic Modulators: A Review for Clinicians

  2014cites this paper
• Fabry disease and cardiovascular involvement.

  2013cites this paper
• Fibrosis: a key feature of Fabry disease with potential therapeutic implications

  2013cites this paper
• Cardiac metabolism in hypertrophy and heart failure: implications for therapy

  2013cites this paper
• Coronary microvascular dysfunction is an early feature of cardiac involvement in patients with Anderson–Fabry disease

  2013cites this paper
• Non-invasive Determination of Myocardial Lipid Content in Fabry Disease by 1H-MR Spectroscopy

  2012cites this paper
• Heart failure highlights in 2010

  2011cites this paper
• Abstract—Cardiomyopathy and arrhythmias can cause morbidity and mortality in childhood. Approximately 5% of inborn errors of metabolism are associated with cardiac involvement. In some metabolic disorders, cardiomyopathy

  2011cites this paper